Pneumococcal vaccine at ICU discharge didn't speed sepsis recovery

Clinical takeaway: Vaccinate sepsis survivors on the usual age and risk indications, not as a strategy to improve their recovery. 

Sepsis survivors leave the ICU medically stable and immunologically altered. The infection that nearly killed them clears, but the immune system it disrupted remains dysregulated, inflamed and depleted at once. That residue is the leading explanation for why these patients keep coming back, and it raises an obvious question. If the defect is in the immune system, can an immune intervention repair it? 

Nearly half of adults who survive sepsis-related critical illness are hospitalized again within a year, and about one in seven dies. In clinic they arrive with a discharge summary, a long medication list, and nothing that modifies the trajectory. A conjugate vaccine is a reasonable place to start, because it engages the T cell and B cell machinery sepsis scrambles, and most of these patients are already vaccine-eligible on age or comorbidity. A randomized, placebo-controlled trial gave 214 adult survivors a single dose on the way out of the ICU and followed them for one year. 

The vaccine did not help. Over 365 days, 43 vaccinated patients had a first infection-related rehospitalization or death, against 38 on placebo, and the event rates ran slightly higher in the vaccine arm. Deaths were few and split evenly, seven and six. Nothing in the primary outcome pointed toward benefit. 

The secondary outcomes leaned the same direction. Reinfections by one year reached 69.3% of the vaccine group versus 59.6% of placebo, and vaccinated patients started antibiotics in primary care sooner. The authors offer a deflating possibility for that gap: infections were counted from diagnosis codes and antibiotic prescriptions rather than cultures, so systemic vaccine effects may have been read as infection and treated accordingly. Severe adverse events were more common after vaccination, 51.9% of patients versus 35.4%, though none were judged vaccine-related. 

The immune response, meanwhile, was real. Antibody levels rose for six of the 13 vaccine serotypes by day 30, and the vaccine nudged T cell and B cell populations toward a more normal balance despite the skewed profile survivors carry out of the ICU. But the response varied widely from patient to patient, and the variation followed a pattern: it fell off with age in men and with rising BMI in women. 

Investigators randomized adult sepsis survivors at 13 general ICUs to a single dose of the 13-valent pneumococcal conjugate vaccine (PCV13) or placebo at step-down from critical care, then tracked them for a year through visits, calls, and linked hospital and primary care records. 

The trial was sized to detect a large effect, so a modest benefit or harm remains unresolved. But nothing here argues against pneumococcal vaccination itself, which most survivors already qualify for, and which US practice now delivers as PCV20 or PCV21 rather than the vaccine studied here. For the patient three weeks out from discharge, the work is still surveillance, and reinfection is the event to anticipate. 

Source: Shankar-Hari M, et al. (2026 Aug 12) Sci Transl Med. A randomized, placebo-controlled trial of 13-valent pneumococcal conjugate vaccination to accelerate immune recovery after sepsis